CA2317441C - Intraocular lens coating compositions - Google Patents
Intraocular lens coating compositions Download PDFInfo
- Publication number
- CA2317441C CA2317441C CA002317441A CA2317441A CA2317441C CA 2317441 C CA2317441 C CA 2317441C CA 002317441 A CA002317441 A CA 002317441A CA 2317441 A CA2317441 A CA 2317441A CA 2317441 C CA2317441 C CA 2317441C
- Authority
- CA
- Canada
- Prior art keywords
- acrylate
- substrate material
- coating
- coating solution
- intraocular lens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S623/00—Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
- Y10S623/924—Material characteristic
- Y10S623/926—Synthetic
Abstract
Intraocular lens coating material for reducing the risk of posterior capsule opification and a method of applying the coating material to an intraocular lens substrate material is disclosed. The coating material is different than the substrate material and consists substantially of at least two aryl acrylic hydrophobic monomers of the formula:
wherein: X is H or CH3; m is 0-10; Y is a single bond, O, S, or NR wherein R is H, CH3, C n H2n+1, wherein n=1-10, iso-OC3H7, C6H5, or CH2C6H5, provided that when m=0, Y is a single bond;
Ar is any aromatic ring which can be unsubstituted or substituted with CH3, C2H5, n-C3H7, iso-C3H7, OCH3, C6H11, Cl, Br, C6H5, or CH2C6H5.
wherein: X is H or CH3; m is 0-10; Y is a single bond, O, S, or NR wherein R is H, CH3, C n H2n+1, wherein n=1-10, iso-OC3H7, C6H5, or CH2C6H5, provided that when m=0, Y is a single bond;
Ar is any aromatic ring which can be unsubstituted or substituted with CH3, C2H5, n-C3H7, iso-C3H7, OCH3, C6H11, Cl, Br, C6H5, or CH2C6H5.
Description
INTRAOCULAR LENS COATING COMPOSITIONS
FIELD OF THE INVENTION
This invention relates to intraocular lenses. In particular, the present invention relates to inti-aocular lens coating compositions for reducing the risk of posterior capsule opacification.
BACKGROUND OF THE INVENTION
Foldable intraocular leris ("IOL") materials can generally be divided into three categories: silicone materials, hydrogel materials, and non-hydrogel acrylic materials. Many materials in each category are known. See, for example, Foldable Intraocular Lenses, IEd. Martin et al., Slack Incorporated, Thorofare, New Jersey (1993). Biiocompatibility varies among different IOL materials within and among each category.
One measure of biocompatability for an IOL can be the incidence of posterior capsule opaciification ("PCO"). A number or factors may be involved in causing and/or controlling PCO. For example, the design and edge sharpness of an IOL may be a factor. See, Nagamoto et al., J. Cataract Refract. Surg., 23:866-872 (1997); and Nagata et al., Jpn. J. Ophthalmol., 40:397-403 (1996).
.:5 See, also, U.S. Patent INos. 5,549,670 and 5,693,094. Another factor appears to be the lens material itself. See, for example, Mandle, "Acrylic lenses cause less posterior capsule opacification than PMMA, silicone IOLs," Ocular Surgery News, Vol. 14. No. 15, p. 23 (1996). See, also, Oshika, et al., "Two Year Clinical Study of a Soft Acrylic Intraocular Lens," J. Cataract. Refract. Surg., 22:104-109 (1996);
and Ursell et al., "Relationship Between Intraocular Lens Biomaterials and Posterior Capsule Opacificatiori," J. Cataract Refract. Surg., 24:352-360 (1998).
One method of addressing the PCO problem involves administering a pharmaceutical agent to the capsular bag area at the time of, or immediately SUBSTITUTE SHEET (RULE 26) after, extracapsular cataract extraction. See, for example, U.S. Patent Nos.
5,576,345 (pharmaceutical agent = the cytotoxic agent taxol or an ophthalmically acceptable derivative); 4,515,794; and 5,370,687. Altematively, the pharmaceutical agent rnay be tethered to the surface of the !OL material. See, for example, U.S. Patent No. 4,918,165. The pharmaceutical agents are intended to kill or prevent the girowth of proliferating cells that might cause PCO
or "secondary cataracts." Yet another method involves the physical destruction or removal of lens epitlielial cells. See, Saika et al., J. Cataract Refract.
Surg., 23:1528-1531 (1997).
Another method of addressing PCO is the prophylactic laser therapy method disclosed in U.S. Patent No. 5,733,276. According to this method, the lens capsule is irradiated with laser irradiation to destroy cells which remain in the lens capsule after extraction of a cataract.
Other methods theorized for reducing the risk of PCO involve adhering the posterior capsule to the IOL at the time of implantation, as in U.S.
Patent No.
5,002,571. According to the '571 patent, a non-biological glue or, preferably, a biological glue, such as fibrin, collagen, or mussel glue, is used to adhere the posterior lens capsule to the posterior surface of an lOL. The glue may be applied over the entire posterior surface of the IOL or just as an annulus around the outer perimeter of the posterior surface of the IOL.
In contrast, U.S. 5,375,611 discloses a method of reducing the risk of PCO by preventing the adherence of the posterior capsule to the IOL. According to the '611 patent, the posterior surface of the lens capsule itself is chemically modified at the time of extracapsular cataract extraction. The chemical modification is achieved by depositing a water-insoluble stable or permanent layer of a cell attachmerit preventing compound onto the posterior surface of the lens capsule. The stable or permanent layer may be a polymer, such as polyethylene glycol, polysaccharides, polyethylenepropylene gylcol, and polyvinyl alcohols.
FIELD OF THE INVENTION
This invention relates to intraocular lenses. In particular, the present invention relates to inti-aocular lens coating compositions for reducing the risk of posterior capsule opacification.
BACKGROUND OF THE INVENTION
Foldable intraocular leris ("IOL") materials can generally be divided into three categories: silicone materials, hydrogel materials, and non-hydrogel acrylic materials. Many materials in each category are known. See, for example, Foldable Intraocular Lenses, IEd. Martin et al., Slack Incorporated, Thorofare, New Jersey (1993). Biiocompatibility varies among different IOL materials within and among each category.
One measure of biocompatability for an IOL can be the incidence of posterior capsule opaciification ("PCO"). A number or factors may be involved in causing and/or controlling PCO. For example, the design and edge sharpness of an IOL may be a factor. See, Nagamoto et al., J. Cataract Refract. Surg., 23:866-872 (1997); and Nagata et al., Jpn. J. Ophthalmol., 40:397-403 (1996).
.:5 See, also, U.S. Patent INos. 5,549,670 and 5,693,094. Another factor appears to be the lens material itself. See, for example, Mandle, "Acrylic lenses cause less posterior capsule opacification than PMMA, silicone IOLs," Ocular Surgery News, Vol. 14. No. 15, p. 23 (1996). See, also, Oshika, et al., "Two Year Clinical Study of a Soft Acrylic Intraocular Lens," J. Cataract. Refract. Surg., 22:104-109 (1996);
and Ursell et al., "Relationship Between Intraocular Lens Biomaterials and Posterior Capsule Opacificatiori," J. Cataract Refract. Surg., 24:352-360 (1998).
One method of addressing the PCO problem involves administering a pharmaceutical agent to the capsular bag area at the time of, or immediately SUBSTITUTE SHEET (RULE 26) after, extracapsular cataract extraction. See, for example, U.S. Patent Nos.
5,576,345 (pharmaceutical agent = the cytotoxic agent taxol or an ophthalmically acceptable derivative); 4,515,794; and 5,370,687. Altematively, the pharmaceutical agent rnay be tethered to the surface of the !OL material. See, for example, U.S. Patent No. 4,918,165. The pharmaceutical agents are intended to kill or prevent the girowth of proliferating cells that might cause PCO
or "secondary cataracts." Yet another method involves the physical destruction or removal of lens epitlielial cells. See, Saika et al., J. Cataract Refract.
Surg., 23:1528-1531 (1997).
Another method of addressing PCO is the prophylactic laser therapy method disclosed in U.S. Patent No. 5,733,276. According to this method, the lens capsule is irradiated with laser irradiation to destroy cells which remain in the lens capsule after extraction of a cataract.
Other methods theorized for reducing the risk of PCO involve adhering the posterior capsule to the IOL at the time of implantation, as in U.S.
Patent No.
5,002,571. According to the '571 patent, a non-biological glue or, preferably, a biological glue, such as fibrin, collagen, or mussel glue, is used to adhere the posterior lens capsule to the posterior surface of an lOL. The glue may be applied over the entire posterior surface of the IOL or just as an annulus around the outer perimeter of the posterior surface of the IOL.
In contrast, U.S. 5,375,611 discloses a method of reducing the risk of PCO by preventing the adherence of the posterior capsule to the IOL. According to the '611 patent, the posterior surface of the lens capsule itself is chemically modified at the time of extracapsular cataract extraction. The chemical modification is achieved by depositing a water-insoluble stable or permanent layer of a cell attachmerit preventing compound onto the posterior surface of the lens capsule. The stable or permanent layer may be a polymer, such as polyethylene glycol, polysaccharides, polyethylenepropylene gylcol, and polyvinyl alcohols.
2 ;SUBSTI'TUTE SHEET (RULE 26) What is needed is a rriethod of making IOLs made of materials having relatively high PCO rat-es more biocompatible by reducing the risk of PCO.
SUMMARY OF THE INVENTION
The present invention relates to IOL coating compositions for making IOL
materials more biocom:patible. More specifically, the present invention relates to a coated intraocular lens comprising a substrate material and a coating material for making the intraocular lens more biocompatible and reducing the risk of posterior capsule opacification, wherein the coating material is different than the substrate material and the coating material consists essentially of at least two aryl acrylic hydrophobic: monorriers.
The present invention also relates to a method for reducing the risk of PCO. The method comprises implanting an IOL containing a posterior surface coating consisting essentially oi: at least two aryl acrylic hydrophobic monomers.
The present invention also relates to a method of applying coating compositions comprisirig at least two aryl acrylic hydrophobic monomers to an 21) IOL. The method of applying the coating comprises the steps of polymerizing the coating material to form an uncross-linked polymer, dissolving the uncross-linked polymerized material to form a coating solution, applying the coating solution to the IOL, and securincI the coating to the IOL's surface.
SUMMARY OF THE INVENTION
The present invention relates to IOL coating compositions for making IOL
materials more biocom:patible. More specifically, the present invention relates to a coated intraocular lens comprising a substrate material and a coating material for making the intraocular lens more biocompatible and reducing the risk of posterior capsule opacification, wherein the coating material is different than the substrate material and the coating material consists essentially of at least two aryl acrylic hydrophobic: monorriers.
The present invention also relates to a method for reducing the risk of PCO. The method comprises implanting an IOL containing a posterior surface coating consisting essentially oi: at least two aryl acrylic hydrophobic monomers.
The present invention also relates to a method of applying coating compositions comprisirig at least two aryl acrylic hydrophobic monomers to an 21) IOL. The method of applying the coating comprises the steps of polymerizing the coating material to form an uncross-linked polymer, dissolving the uncross-linked polymerized material to form a coating solution, applying the coating solution to the IOL, and securincI the coating to the IOL's surface.
3 SUBSTI'I'UTE SHEET (RULE 26) DETAILED DESCRIPTION OF THE INVENTION
According to the present invention, IOL's are coated with a composition consisting essentially of at least two monomers of Formula I below.
x I
CH2=C-COO-(CHZ)m-y-Ar ( I ) wherein: X is H or CH3;
m is 0-10;
Y is nothing, 0, S, or NR wherein R is H, CH3, CõH2R+1 (n=1-10) iso-OC3H7, C6H5, or CH2C6H5;
Ar is any aromatic ring which can be unsubstituted or substituted with CH3, C2H5, n-C3H7, iso-C3H7, OCH3, C6H11, Cl, Br, C6H5 or CH2C6H5 , According to one aspect of the present invention, there is provided a coated intraocular lens compris-ng a substrate material and a coating material for makinq the intraocular lens more biocompatible and reducing the risk of posterior capsule opacification, wherein the coatinq material is different than the substrate material and the coating material consists substantially of at least two aryl acrylic hydrophobic monomers of the formula (I) x I
CH2=C-COO-(CH2)m-y-A1-wherein: X is H or CH3; m is 0-10; Y is a single bond, 0, S, or NR wherein R is H, CH3, CnH2n+l, wherein n=1-10, iso-0C3H7, C6H5, or CH2C6H5, provided that when m=0, Y is a single bond;
Ar is any aromatic ring which can be unsubsti.tuted or
According to the present invention, IOL's are coated with a composition consisting essentially of at least two monomers of Formula I below.
x I
CH2=C-COO-(CHZ)m-y-Ar ( I ) wherein: X is H or CH3;
m is 0-10;
Y is nothing, 0, S, or NR wherein R is H, CH3, CõH2R+1 (n=1-10) iso-OC3H7, C6H5, or CH2C6H5;
Ar is any aromatic ring which can be unsubstituted or substituted with CH3, C2H5, n-C3H7, iso-C3H7, OCH3, C6H11, Cl, Br, C6H5 or CH2C6H5 , According to one aspect of the present invention, there is provided a coated intraocular lens compris-ng a substrate material and a coating material for makinq the intraocular lens more biocompatible and reducing the risk of posterior capsule opacification, wherein the coatinq material is different than the substrate material and the coating material consists substantially of at least two aryl acrylic hydrophobic monomers of the formula (I) x I
CH2=C-COO-(CH2)m-y-A1-wherein: X is H or CH3; m is 0-10; Y is a single bond, 0, S, or NR wherein R is H, CH3, CnH2n+l, wherein n=1-10, iso-0C3H7, C6H5, or CH2C6H5, provided that when m=0, Y is a single bond;
Ar is any aromatic ring which can be unsubsti.tuted or
4 substituted with CH3, C2H5, n-C3H7, iso-C3H-,, OCH3, C(;Hll, Cl, Br, C6H5, or CH2C6H5.
According to another aspect of the present invention, there is provided a method of applying a coating material to an intraocular lens substrate material, wherein the coating material and the substrate material are different and the substrate material comprises an anterior surface and a posterior surface, comprising the steps of a) polymerizing a coating composition consisting substantially of at least two aryl acrylic hydrophobic monomers of the formula x I
CH2=C-COO-(CH2)õ-Y-Ar ( I ) wherein: X is H or CH3; m is 0-10; Y is a single bond, 0, S, or NR wherein R is H, CH3, CnH2n+l, wherein n=l-l0, i.so-0C3H7, C6-H5, or CH2C6H5, provided that when m=0, Y is a sirigle bond;
Ar is any aromatic ring which can be unsubstituted or substituted with CH3, C2H5, n-C3H7, iso-C3H-,, OCH3, C(;H11, Cl, Br, C6H5, or CH2C6H5; and a first stage polymerization initiator selected from the group consisting of thermal initiators and photoinitiators, to form an uncross-linked polymer; b) dissolving the uncross-linked polymer f:ormed in step (a) in a solvent to form a coating solution;
c) applying the coating solution formed in step (b) to the substrate material; and d) securing the coating solution to the substrate material by activating a second-stage cross-linking agent, provided that at least one of the coating composition of step (a) and the coating solution of: step (b) contains the second-stage cross-linking agent, wher.ein the second-stage cross-linking agent is selected from the group 4a consisting of dibenzoyl peroxide; substituted dibenzoyl peroxide compounds; and dicumyl peroxide.
According to yet another aspect of the present invention, there is provided a coated intraocular lens comprising a substrate material and a coating material for making the intraocular lens more biocompatible and reducing the risk of posterior capsule opacification, wherein the coating material is different than the substrate material and the coating material consists substantially of at least two aryl acrylic hydrophobic monomers of the formula x I
CH2=C-COO-(CH2)m y-Ar ( I ).
wherein: X is H or CH3; m is 0-10; Y is a single bond, 0, S, or NR wherein R is H, CH3, CnH2n+1, wherein n=1-10, iso-OC3H7r C6H5, or CH2C6H5, provided that when m=0, Y is a single bond;
Ar is any aromatic ring which can be unsubstituted or substituted with CH3, C2H5, n-C3H7, iso-C3H7, OCH3, C6H11, Cl, Br, C6H5, or CH2C6H5; and one or more ingredients selected from the group consisting of UV absorbing compounds and blue-light absorbing compounds.
According to still another aspect of the present invention, there is provided a method of applying a coating material to an intraocular lens substrate material, wherein the coating material and the substrate material are different and the substrate material comprises an anterior surface and a posterior surface, comprising the steps of a) polymerizing a coating composition consisting substantially of at least two aryl acrylic hydrophobic monomers of the formula 4b x I
CH2=C-C00-(CH2)m y-Ar ( I ) wherein: X is H or CH3; m is 0-10; Y is a single bond, 0, S, or NR wherein R is H, CH3, CnH2n+ir wherein n=1-10, iso-0C3H7, C6H5r or CH2C6H5, provided that when m=0, Y is a single bond;
Ar is any aromatic ring which can be unsubstituted or substituted with CH3, C2H5, n-C3H7, iS0-C3H7, OCH3, C6H11, Cl, Br, C6H5, or CH2C6H5; one or more ingredients selected from the group consisting of UV absorbing compounds and blue-light absorbing compounds; and a first stage polymerization initiator selected from the group consisting of thermal initiators and photoinitiators, to form an uncross-linked polymer; b) dissolving the uncross-linked polymer formed in step (a) in a solvent to form a coating solution; c) applying the coating solution formed in step (b) to the substrate material; and d) securing the coating solution to the substrate material by activating a second-stage cross-linking agent, provided that at least one of the coating composition of step (a) and the coating solution of step (b) contains the second-stage cross-linking agent, wherein the second-stage cross-linking agent is selected from the group consisting of dibenzoyl peroxide; substituted dibenzoyl peroxide compounds; and dicumyl peroxide.
According to a further aspect of the present invention, there is provided a method of applying a coating material to an intraocular lens substrate material, wherein the coating material and the substrate material are different and the substrate material comprises an anterior surface and a posterior surface, comprising the steps of a) polymerizing a coating composition consisting substantially of at least two aryl acrylic hydrophobic monomers of the formula 4c x I
CH2=C-COO-(CH2)m y-Ar ( I ) wherein: X is H or CH3; m is 0-10; Y is a single bond, 0, S, or NR wherein R is H, CH3r CnH2õ+1r wherein n=1-10, iso-0C3H7r C6H5, or CH2C6H5, provided that when m=0, Y is a single bond;
Ar is any aromatic ring which can be unsubstituted or substituted with CH3r C2H5, n-C3H7, iS0-C3H7, OCH3, C6H11, Cl, Br, C6H5, or CH2C6H5; and a first stage polymerization initiator selected from the group consisting of thermal initiators and photoinitiators, to form an uncross-linked polymer; b) dissolving the uncross-linked polymer formed in step (a) in a solvent to form a coating solution, wherein the coating solution further comprises one or more ingredients selected from the group consisting of UV
absorbing compounds and blue-light absorbing compounds; c) applying the coating solution formed in step (b) to the substrate material; and d) securing the coating solution to the substrate material by activating a second-stage cross-linking agent, provided that at least one of the coating composition of step (a) and the coating solution of step (b) contains the second-stage cross-linking agent, wherein the second-stage cross-linking agent is selected from the group consisting of dibenzoyl peroxide; substituted dibenzoyl peroxide compounds; and dicumyl peroxide.
Monomers of Formula I are known and include, but are not limited to: 2-phenoxyethyl acrylate;
2-phenylethylthio acrylate; 2-phenylethylamino acrylate;
phenyl acrylate; benzyl acrylate; 2-phenylethyl acrylate;
3-phenylpropyl acrylate; 3-phenoxypropyl acrylate;
4-phenylbutyl acrylate; 4-phenoxybutyl acrylate;
4-methylphenyl acrylate; 4-methylbenzyl acrylate;
2,2-methylphenylethyl acrylate; 2,3-methylphenylethyl 4d acrylate; 2,4-methylphenylethyl acrylate; and their corresponding methacrylate compounds. These acrylic/methacrylic monomers and others are disclosed in U.S. Patent No. 5,290,892.
Preferred monomers of Formula I are those where m is 2-4; Y is a single bond or 0; and Ar is phenyl. Most preferred are 2-phenylethyl acrylate; 2-phenoxyethyl acrylate; 3-phenylpropyl acrylate; 3-phenoxypropyl acrylate;
4-phenylbutyl acrylate; 4-phenoxybutyl acrylate; and their corresponding methacrylate compounds. The IOL coating compo.sitions of the present invention preferably contain at least one monomer of Formula I that is a methacrylate monomer (X=CH3) and at least one monomer of Formula I that is an acrylate monomer (X=H). Most preferred are coating compositions consisting essentially of at least 4e one monomer of Formula I that is a methacrylate monomer (X = CH3 ) and at least one monomer of Formuia l that is an acrylate monomer (X = H), wherein the total amount of the acrylate monomer(s) of Formula I is greater than the total amount of methacrylate monomer(s) of Formula I. In one preferred embodiment, the IOL coating composition consists essentially of 2-phenylethyl acrylate and phenylethyl methacrylate, and more preferably, about 65 % (w/w) of 2-phenyiethyiacryfate and about 30 %(w/w) of 2-phenylethyl methacrylate.
The IOL coating compositions also comprise a first stage polymerization initiator selected from the group consisting of thermal initiators and photoinitiators. The first stage polymerization initiator should be chosen such that it can be activated without causing cross-linking. In the event that the IOL
coating composition contains a second stage cross-linking agent prior to stage polymerization and the first stage polymerization initiator is selected from the group consisting of low-temperature thermal initiators and photoinitiators. As used herein, "low-temperature thermal initiator" means a thermal initiator that has an activation temperature lower than the activation temperature of the chosen second stage cross-linking agent. Suitable low temperature thernial initiators include azo free-radical initiators, such as 2,2'-azobis(isobutyronitrile) 20 ["AIBN"] and 2,2'-azobis(2,4-dimethylvalerontrile). Suitable photoinitiators include UV- and blue-light photoiriitiators. Many such photoinitiators are known.
Preferred blue-light photoinitiators are benzoylphosphine oxide initiators, such as 2,4,6-trimethyl-benzoyidiphenyiophosphine oxide; bis-(2,6-dichlorobenzoyl)=-4-N-propylphenyl-phosphine oxide; and bis-(2,6-dichiorobenzoyl)-4-N-25 butylpheny{-phosphine oxide. Most preferred are 2,4,6-trimethyl-benzoyldiphenylophosphine oxide, commercially available as Lucirin TF'O
from BASF Corporation (Charlotte, North Carolina), and Darocur 4265 from Ciba Geigy. See, for example, U.S. Patent No. 5,891,931.
30 The amount of the first stage polymerization initiator in the coating compositions of the present invention will depend upon the curing conditions.
In general, however, the amouint of first stage polymerization initiator contained in the mixture to be polymerized in stage of the present invention will be about 3 % (w/w) or less, preferably about 2 % (w/w) or less, and most preferably about 1 % (w/w).
In addition to the monomers of Formula I and the first stage polymerization initiator, a second stage cross-linking agent is optionally added to the coating compositions of the present invention prior to stage 1 polymerization. If noi: preserit during the stage 1 polymerization, then the second stage cross-linking agent is added at the time the stage 1 polymer is dissolved to form a coating solution. Second stage cross-linking agents are selected from the group consisting of dibenzoyl peroxide, substituted dibenzoyl peroxide compounds, and dicumyl peroxide, many of which are commercially available. For exarnple, dicumyl peroxide is available from Hercules IS incorporated (Wilmington, Delaware). Suitable substituted dibenzoyl peroxide compounds include 2,4-dichlorodibenzoylperoxide. Dicumyl peroxide and dibenzoyl peroxide are preferred for use with coating compositions consisting essentially of 2-phenylethyl acrylate and 2-phenylethyl methacrylate.
2C Whether added prior to stage 1 poiymerization or at the time the stage I
polymer is dissolved to form a coating solution, the amount of the second stage cross-linking agent contained in the coating compositions of the present invention will depend upon, arnong other factors, the degree of cross-linking desired. In general, however, the amount of second stage cross-linking agent 25 in necessary to cross-lirik the coating composition and secure it to the IOL optic surface will be about 1 - 10 % (w/w), and preferably about 3 - 5%(w/w).
In order to prevent prerriature cross-linking, the coating compositions of the present invention do not contain any monomers having more than one 30 unsaturated bond. Such inigredients include the common cross-linking monomers ethyleneglycol dimiethacrylate; diethylene glycol dimethacrylate;
ethyleneglycol diacrylate; allyl methacrylates; allyl acrylates; 1,3-propanediol SUBSTITUTE SHEET (RULE 26) dimethacrylate; 1,6-he:xanediol dimethacrylate; 1,4-butanediol dimethacrylate;
polyethyleneoxide diacrylates; and the like.
The coating ccimpositions optionally include one or more ingredients selected from the group consisting of UV absorbers and blue-light blocking colorants. The UV absorber and/or blue-light blocking colorant may be added either prior to stage "I polymerization or at the time the stage 1 polymer is dissolved to form a coaiting solution. If added prior to stage 1 polymerization, the stage 1 polymerization initiator should be chosen so that the UV absorber and/or blue-light blocking colorant do not significantly interfere with the stage 1 polymerization.
Ultraviolet absorbing chromophores can be any compound which absorbs light having ai wavelength shorter than about 400 nm, but does not absorb any substantial amount of visible light. It is preferred to use an ultraviolet absorbing compound that is copolymerizable with the monomers of Formula I or the can be covalently bound to the coating/IOL substrate during the second stage cross-linking. Suitable copolymerizable ultraviolet absorbing compounds are the substituted 2-hydroxybenzophenones disclosed in U.S.
Patent No. 4,304,895 and the 2-hydroxy-5-acryloxyphenyl-2H-benzotriazoles disclosed in U.S. Patent Nc-. 4,528,311. The most preferred ultraviolet absorbing compound is 2-(3'-methallyl-2'-hydroxy-5'-methyl phenyl) benzotriazole.
Z:s If a UV-absorber is added prior to stage 1 polymerization, it is unlikely that a UV polymerization initiator may be used as the first stage polymerization initiator. In such cases, the first stage polymerization initiator will likely have to be either a thermal initiator or a blue-light initiator in order to avoid interference with the UV-absorber.
If a blue-light absorbing compound, e.g. a yellow dye, is included in the coating compositions of the present invention prior to stage I polymerization, then the first stage polymerization initiator will likely not be a blue-light SUBSTITUTE SHEET (RULE 26) photoinitiator. In the event the coating composition contains both a UV-absorber and a blue-light absorbing compound prior to stage 1 polymerization, the first stage polymerization initiator will likely be a thermal initiatior.
Preferably, the blue-light absorber is copolymerizable with the monomers of Formula 1 or can be covalently bound to the coating/IOL substrate during the second stage cross-linking. Suitable polymerizable blue-light blocking chromophores include those disclosed in U.S. Patent No. 5,470,932.
The coating composition of this invention is prepared by forming a ,o mixture comprising, in the desired proportions, the monomers of Formula I, the first stage polymerization initiator, and optionally one or more of the ingredients selected from the group consisting of second stage cross-linking agents, UV
absorbing compounds, and blue-light absorbing compounds. The coating composition is then polymerized by activating (e.g., using heat, UV- or blue-light) the first stage polymerization linitiator, being careful not to activate the second stage cross-linking agent, if present.
In the case where the first stage polymerization initiator is a low temperature thermal initiator and the second stage cross-linking agent is dicumyl :o peroxide, the thermal initiator rnay be activated by exposure to temperatures of up to approximately 50 C or so without activating the dicumyl peroxide. In the case where the second stage cross-linking agent is a dibenzoyl peroxide or a substituted dibenzoyl peroxide, the curing temperature for stage 1 will generally be about 40 C or less. The curing parameters, e.g., length of exposure and 25 temperature or intensilty of light source, are preferably chosen to accomplish complete polymerizatioin.
After the first stage polymerization is complete, the resulting polymer is dissolved in a solvent to fomi a coating solution. Suitable solvents include 30 ketones, such as acetone, methylethylketone and 2-pentanone. The preferred solvent for use with coating coimpositions consisting essentially of 2-phenylethyl acrylate and 2-phenylethyl methacrylate is 2-pentanone. For the particular coating composition consisting essentially of 2-phenylethyl acrylate and 2-SUBSTITUTE SHEET (RULE 26) phenylethyl methacrylate, acetone did not work and methylethyi ketone worked only marginally well as a solvent. The solvent should be chosen such that it has an evaporation rate that is neither too fast (resulting in a hazy or frosty coating) nor too slow (meanirig the solvent seems to never dry). Addftionally, the application time for the coating should be controlled to minimize any swelling of the substrate material ;so that the there is little or no disturbance of the coating's or substrate's surface. 'The concentration of the dissolved polymer is not essential, and can be, for exarnple, 5 - 8% (w/w) of the coating solution. At this time, the second stage cross-linking agent, and any UV absorber or blue-light absorbing compound rnay be added, if not already contained in the mixture that was polymerized in stage 1.
After the coatirig solution has been formed, it is applied to the IOL
material ("substrate material") to be coated. The substrate material may .15 comprise any ophthainiically acceptable material, such as silicone, hydrogels or hydrophobic acrylic materials. If the substrate is a hydrogel material having a linear swell factor of about rli % or greater, plasticizers should be used to minimize swelling effects during hydration. The plasticizer does not change the water content of the tiydrogel material, but changes the swell factor. When ::o hydrated, water exchariges witti the plasticizer.
The coatings of the present invention may be used in conjunction with substrate materials intended for use as a "hard" IOL (that is inserted in an unfolded state) or a"'fofdable" or "soft" IOL (that is inserted in a folded or 25 compressed state). For example, the IOL material to be coated could be those IOL materiais disclosedl in U.S. Patent Nos. 5,693,095 or 5,331,073. A
preferred IOL material comprises 2-phenylethyl acrylate and 2-hydroxyethyl methacrylate.
AIl that is necessary is i,that the coating material be different than the IOL
material to be coated. Thus, ttie IOL material to be coated can comprise two or more :o monomers of formula I, as long as at least one of the two or more monomers of formula I contained in the coating material is different from those comprising the IOL material. The coating may be applied to the portion of the IOL material constituting the optic's entire posterior surface or to only a peripheral band of the SUBSTITUTE SHEET (RULE 26) posterior surface. Additionally, the optic's anterior surface or a peripheral band of the anterior surface may be coated.
In order to prepare the IOL material to be coated so that it is capable of receiving the coating, it may be necessary or desirable to expose the surface to be coated to a reactive plasma gas prior to applying the coating composition of the present invention. Suitable reactive plasma gases include oxidizing gases, such as oxygen gas. A suitable plasma chamber is the P2CIM B-Series plasma chamber made by Advanced Plasma Systems, Inc. Using such a chamber, suitable plasma parameters include: power = 400 W, plasma gas = oxygen;
pressure of the plasma gas = 225 mTorr; exposure time = 4 - 6 minutes.
The coating solution may be applied to the IOL material to be coated by dip coating or spin coating, for example. The thickness of the coating should be
According to another aspect of the present invention, there is provided a method of applying a coating material to an intraocular lens substrate material, wherein the coating material and the substrate material are different and the substrate material comprises an anterior surface and a posterior surface, comprising the steps of a) polymerizing a coating composition consisting substantially of at least two aryl acrylic hydrophobic monomers of the formula x I
CH2=C-COO-(CH2)õ-Y-Ar ( I ) wherein: X is H or CH3; m is 0-10; Y is a single bond, 0, S, or NR wherein R is H, CH3, CnH2n+l, wherein n=l-l0, i.so-0C3H7, C6-H5, or CH2C6H5, provided that when m=0, Y is a sirigle bond;
Ar is any aromatic ring which can be unsubstituted or substituted with CH3, C2H5, n-C3H7, iso-C3H-,, OCH3, C(;H11, Cl, Br, C6H5, or CH2C6H5; and a first stage polymerization initiator selected from the group consisting of thermal initiators and photoinitiators, to form an uncross-linked polymer; b) dissolving the uncross-linked polymer f:ormed in step (a) in a solvent to form a coating solution;
c) applying the coating solution formed in step (b) to the substrate material; and d) securing the coating solution to the substrate material by activating a second-stage cross-linking agent, provided that at least one of the coating composition of step (a) and the coating solution of: step (b) contains the second-stage cross-linking agent, wher.ein the second-stage cross-linking agent is selected from the group 4a consisting of dibenzoyl peroxide; substituted dibenzoyl peroxide compounds; and dicumyl peroxide.
According to yet another aspect of the present invention, there is provided a coated intraocular lens comprising a substrate material and a coating material for making the intraocular lens more biocompatible and reducing the risk of posterior capsule opacification, wherein the coating material is different than the substrate material and the coating material consists substantially of at least two aryl acrylic hydrophobic monomers of the formula x I
CH2=C-COO-(CH2)m y-Ar ( I ).
wherein: X is H or CH3; m is 0-10; Y is a single bond, 0, S, or NR wherein R is H, CH3, CnH2n+1, wherein n=1-10, iso-OC3H7r C6H5, or CH2C6H5, provided that when m=0, Y is a single bond;
Ar is any aromatic ring which can be unsubstituted or substituted with CH3, C2H5, n-C3H7, iso-C3H7, OCH3, C6H11, Cl, Br, C6H5, or CH2C6H5; and one or more ingredients selected from the group consisting of UV absorbing compounds and blue-light absorbing compounds.
According to still another aspect of the present invention, there is provided a method of applying a coating material to an intraocular lens substrate material, wherein the coating material and the substrate material are different and the substrate material comprises an anterior surface and a posterior surface, comprising the steps of a) polymerizing a coating composition consisting substantially of at least two aryl acrylic hydrophobic monomers of the formula 4b x I
CH2=C-C00-(CH2)m y-Ar ( I ) wherein: X is H or CH3; m is 0-10; Y is a single bond, 0, S, or NR wherein R is H, CH3, CnH2n+ir wherein n=1-10, iso-0C3H7, C6H5r or CH2C6H5, provided that when m=0, Y is a single bond;
Ar is any aromatic ring which can be unsubstituted or substituted with CH3, C2H5, n-C3H7, iS0-C3H7, OCH3, C6H11, Cl, Br, C6H5, or CH2C6H5; one or more ingredients selected from the group consisting of UV absorbing compounds and blue-light absorbing compounds; and a first stage polymerization initiator selected from the group consisting of thermal initiators and photoinitiators, to form an uncross-linked polymer; b) dissolving the uncross-linked polymer formed in step (a) in a solvent to form a coating solution; c) applying the coating solution formed in step (b) to the substrate material; and d) securing the coating solution to the substrate material by activating a second-stage cross-linking agent, provided that at least one of the coating composition of step (a) and the coating solution of step (b) contains the second-stage cross-linking agent, wherein the second-stage cross-linking agent is selected from the group consisting of dibenzoyl peroxide; substituted dibenzoyl peroxide compounds; and dicumyl peroxide.
According to a further aspect of the present invention, there is provided a method of applying a coating material to an intraocular lens substrate material, wherein the coating material and the substrate material are different and the substrate material comprises an anterior surface and a posterior surface, comprising the steps of a) polymerizing a coating composition consisting substantially of at least two aryl acrylic hydrophobic monomers of the formula 4c x I
CH2=C-COO-(CH2)m y-Ar ( I ) wherein: X is H or CH3; m is 0-10; Y is a single bond, 0, S, or NR wherein R is H, CH3r CnH2õ+1r wherein n=1-10, iso-0C3H7r C6H5, or CH2C6H5, provided that when m=0, Y is a single bond;
Ar is any aromatic ring which can be unsubstituted or substituted with CH3r C2H5, n-C3H7, iS0-C3H7, OCH3, C6H11, Cl, Br, C6H5, or CH2C6H5; and a first stage polymerization initiator selected from the group consisting of thermal initiators and photoinitiators, to form an uncross-linked polymer; b) dissolving the uncross-linked polymer formed in step (a) in a solvent to form a coating solution, wherein the coating solution further comprises one or more ingredients selected from the group consisting of UV
absorbing compounds and blue-light absorbing compounds; c) applying the coating solution formed in step (b) to the substrate material; and d) securing the coating solution to the substrate material by activating a second-stage cross-linking agent, provided that at least one of the coating composition of step (a) and the coating solution of step (b) contains the second-stage cross-linking agent, wherein the second-stage cross-linking agent is selected from the group consisting of dibenzoyl peroxide; substituted dibenzoyl peroxide compounds; and dicumyl peroxide.
Monomers of Formula I are known and include, but are not limited to: 2-phenoxyethyl acrylate;
2-phenylethylthio acrylate; 2-phenylethylamino acrylate;
phenyl acrylate; benzyl acrylate; 2-phenylethyl acrylate;
3-phenylpropyl acrylate; 3-phenoxypropyl acrylate;
4-phenylbutyl acrylate; 4-phenoxybutyl acrylate;
4-methylphenyl acrylate; 4-methylbenzyl acrylate;
2,2-methylphenylethyl acrylate; 2,3-methylphenylethyl 4d acrylate; 2,4-methylphenylethyl acrylate; and their corresponding methacrylate compounds. These acrylic/methacrylic monomers and others are disclosed in U.S. Patent No. 5,290,892.
Preferred monomers of Formula I are those where m is 2-4; Y is a single bond or 0; and Ar is phenyl. Most preferred are 2-phenylethyl acrylate; 2-phenoxyethyl acrylate; 3-phenylpropyl acrylate; 3-phenoxypropyl acrylate;
4-phenylbutyl acrylate; 4-phenoxybutyl acrylate; and their corresponding methacrylate compounds. The IOL coating compo.sitions of the present invention preferably contain at least one monomer of Formula I that is a methacrylate monomer (X=CH3) and at least one monomer of Formula I that is an acrylate monomer (X=H). Most preferred are coating compositions consisting essentially of at least 4e one monomer of Formula I that is a methacrylate monomer (X = CH3 ) and at least one monomer of Formuia l that is an acrylate monomer (X = H), wherein the total amount of the acrylate monomer(s) of Formula I is greater than the total amount of methacrylate monomer(s) of Formula I. In one preferred embodiment, the IOL coating composition consists essentially of 2-phenylethyl acrylate and phenylethyl methacrylate, and more preferably, about 65 % (w/w) of 2-phenyiethyiacryfate and about 30 %(w/w) of 2-phenylethyl methacrylate.
The IOL coating compositions also comprise a first stage polymerization initiator selected from the group consisting of thermal initiators and photoinitiators. The first stage polymerization initiator should be chosen such that it can be activated without causing cross-linking. In the event that the IOL
coating composition contains a second stage cross-linking agent prior to stage polymerization and the first stage polymerization initiator is selected from the group consisting of low-temperature thermal initiators and photoinitiators. As used herein, "low-temperature thermal initiator" means a thermal initiator that has an activation temperature lower than the activation temperature of the chosen second stage cross-linking agent. Suitable low temperature thernial initiators include azo free-radical initiators, such as 2,2'-azobis(isobutyronitrile) 20 ["AIBN"] and 2,2'-azobis(2,4-dimethylvalerontrile). Suitable photoinitiators include UV- and blue-light photoiriitiators. Many such photoinitiators are known.
Preferred blue-light photoinitiators are benzoylphosphine oxide initiators, such as 2,4,6-trimethyl-benzoyidiphenyiophosphine oxide; bis-(2,6-dichlorobenzoyl)=-4-N-propylphenyl-phosphine oxide; and bis-(2,6-dichiorobenzoyl)-4-N-25 butylpheny{-phosphine oxide. Most preferred are 2,4,6-trimethyl-benzoyldiphenylophosphine oxide, commercially available as Lucirin TF'O
from BASF Corporation (Charlotte, North Carolina), and Darocur 4265 from Ciba Geigy. See, for example, U.S. Patent No. 5,891,931.
30 The amount of the first stage polymerization initiator in the coating compositions of the present invention will depend upon the curing conditions.
In general, however, the amouint of first stage polymerization initiator contained in the mixture to be polymerized in stage of the present invention will be about 3 % (w/w) or less, preferably about 2 % (w/w) or less, and most preferably about 1 % (w/w).
In addition to the monomers of Formula I and the first stage polymerization initiator, a second stage cross-linking agent is optionally added to the coating compositions of the present invention prior to stage 1 polymerization. If noi: preserit during the stage 1 polymerization, then the second stage cross-linking agent is added at the time the stage 1 polymer is dissolved to form a coating solution. Second stage cross-linking agents are selected from the group consisting of dibenzoyl peroxide, substituted dibenzoyl peroxide compounds, and dicumyl peroxide, many of which are commercially available. For exarnple, dicumyl peroxide is available from Hercules IS incorporated (Wilmington, Delaware). Suitable substituted dibenzoyl peroxide compounds include 2,4-dichlorodibenzoylperoxide. Dicumyl peroxide and dibenzoyl peroxide are preferred for use with coating compositions consisting essentially of 2-phenylethyl acrylate and 2-phenylethyl methacrylate.
2C Whether added prior to stage 1 poiymerization or at the time the stage I
polymer is dissolved to form a coating solution, the amount of the second stage cross-linking agent contained in the coating compositions of the present invention will depend upon, arnong other factors, the degree of cross-linking desired. In general, however, the amount of second stage cross-linking agent 25 in necessary to cross-lirik the coating composition and secure it to the IOL optic surface will be about 1 - 10 % (w/w), and preferably about 3 - 5%(w/w).
In order to prevent prerriature cross-linking, the coating compositions of the present invention do not contain any monomers having more than one 30 unsaturated bond. Such inigredients include the common cross-linking monomers ethyleneglycol dimiethacrylate; diethylene glycol dimethacrylate;
ethyleneglycol diacrylate; allyl methacrylates; allyl acrylates; 1,3-propanediol SUBSTITUTE SHEET (RULE 26) dimethacrylate; 1,6-he:xanediol dimethacrylate; 1,4-butanediol dimethacrylate;
polyethyleneoxide diacrylates; and the like.
The coating ccimpositions optionally include one or more ingredients selected from the group consisting of UV absorbers and blue-light blocking colorants. The UV absorber and/or blue-light blocking colorant may be added either prior to stage "I polymerization or at the time the stage 1 polymer is dissolved to form a coaiting solution. If added prior to stage 1 polymerization, the stage 1 polymerization initiator should be chosen so that the UV absorber and/or blue-light blocking colorant do not significantly interfere with the stage 1 polymerization.
Ultraviolet absorbing chromophores can be any compound which absorbs light having ai wavelength shorter than about 400 nm, but does not absorb any substantial amount of visible light. It is preferred to use an ultraviolet absorbing compound that is copolymerizable with the monomers of Formula I or the can be covalently bound to the coating/IOL substrate during the second stage cross-linking. Suitable copolymerizable ultraviolet absorbing compounds are the substituted 2-hydroxybenzophenones disclosed in U.S.
Patent No. 4,304,895 and the 2-hydroxy-5-acryloxyphenyl-2H-benzotriazoles disclosed in U.S. Patent Nc-. 4,528,311. The most preferred ultraviolet absorbing compound is 2-(3'-methallyl-2'-hydroxy-5'-methyl phenyl) benzotriazole.
Z:s If a UV-absorber is added prior to stage 1 polymerization, it is unlikely that a UV polymerization initiator may be used as the first stage polymerization initiator. In such cases, the first stage polymerization initiator will likely have to be either a thermal initiator or a blue-light initiator in order to avoid interference with the UV-absorber.
If a blue-light absorbing compound, e.g. a yellow dye, is included in the coating compositions of the present invention prior to stage I polymerization, then the first stage polymerization initiator will likely not be a blue-light SUBSTITUTE SHEET (RULE 26) photoinitiator. In the event the coating composition contains both a UV-absorber and a blue-light absorbing compound prior to stage 1 polymerization, the first stage polymerization initiator will likely be a thermal initiatior.
Preferably, the blue-light absorber is copolymerizable with the monomers of Formula 1 or can be covalently bound to the coating/IOL substrate during the second stage cross-linking. Suitable polymerizable blue-light blocking chromophores include those disclosed in U.S. Patent No. 5,470,932.
The coating composition of this invention is prepared by forming a ,o mixture comprising, in the desired proportions, the monomers of Formula I, the first stage polymerization initiator, and optionally one or more of the ingredients selected from the group consisting of second stage cross-linking agents, UV
absorbing compounds, and blue-light absorbing compounds. The coating composition is then polymerized by activating (e.g., using heat, UV- or blue-light) the first stage polymerization linitiator, being careful not to activate the second stage cross-linking agent, if present.
In the case where the first stage polymerization initiator is a low temperature thermal initiator and the second stage cross-linking agent is dicumyl :o peroxide, the thermal initiator rnay be activated by exposure to temperatures of up to approximately 50 C or so without activating the dicumyl peroxide. In the case where the second stage cross-linking agent is a dibenzoyl peroxide or a substituted dibenzoyl peroxide, the curing temperature for stage 1 will generally be about 40 C or less. The curing parameters, e.g., length of exposure and 25 temperature or intensilty of light source, are preferably chosen to accomplish complete polymerizatioin.
After the first stage polymerization is complete, the resulting polymer is dissolved in a solvent to fomi a coating solution. Suitable solvents include 30 ketones, such as acetone, methylethylketone and 2-pentanone. The preferred solvent for use with coating coimpositions consisting essentially of 2-phenylethyl acrylate and 2-phenylethyl methacrylate is 2-pentanone. For the particular coating composition consisting essentially of 2-phenylethyl acrylate and 2-SUBSTITUTE SHEET (RULE 26) phenylethyl methacrylate, acetone did not work and methylethyi ketone worked only marginally well as a solvent. The solvent should be chosen such that it has an evaporation rate that is neither too fast (resulting in a hazy or frosty coating) nor too slow (meanirig the solvent seems to never dry). Addftionally, the application time for the coating should be controlled to minimize any swelling of the substrate material ;so that the there is little or no disturbance of the coating's or substrate's surface. 'The concentration of the dissolved polymer is not essential, and can be, for exarnple, 5 - 8% (w/w) of the coating solution. At this time, the second stage cross-linking agent, and any UV absorber or blue-light absorbing compound rnay be added, if not already contained in the mixture that was polymerized in stage 1.
After the coatirig solution has been formed, it is applied to the IOL
material ("substrate material") to be coated. The substrate material may .15 comprise any ophthainiically acceptable material, such as silicone, hydrogels or hydrophobic acrylic materials. If the substrate is a hydrogel material having a linear swell factor of about rli % or greater, plasticizers should be used to minimize swelling effects during hydration. The plasticizer does not change the water content of the tiydrogel material, but changes the swell factor. When ::o hydrated, water exchariges witti the plasticizer.
The coatings of the present invention may be used in conjunction with substrate materials intended for use as a "hard" IOL (that is inserted in an unfolded state) or a"'fofdable" or "soft" IOL (that is inserted in a folded or 25 compressed state). For example, the IOL material to be coated could be those IOL materiais disclosedl in U.S. Patent Nos. 5,693,095 or 5,331,073. A
preferred IOL material comprises 2-phenylethyl acrylate and 2-hydroxyethyl methacrylate.
AIl that is necessary is i,that the coating material be different than the IOL
material to be coated. Thus, ttie IOL material to be coated can comprise two or more :o monomers of formula I, as long as at least one of the two or more monomers of formula I contained in the coating material is different from those comprising the IOL material. The coating may be applied to the portion of the IOL material constituting the optic's entire posterior surface or to only a peripheral band of the SUBSTITUTE SHEET (RULE 26) posterior surface. Additionally, the optic's anterior surface or a peripheral band of the anterior surface may be coated.
In order to prepare the IOL material to be coated so that it is capable of receiving the coating, it may be necessary or desirable to expose the surface to be coated to a reactive plasma gas prior to applying the coating composition of the present invention. Suitable reactive plasma gases include oxidizing gases, such as oxygen gas. A suitable plasma chamber is the P2CIM B-Series plasma chamber made by Advanced Plasma Systems, Inc. Using such a chamber, suitable plasma parameters include: power = 400 W, plasma gas = oxygen;
pressure of the plasma gas = 225 mTorr; exposure time = 4 - 6 minutes.
The coating solution may be applied to the IOL material to be coated by dip coating or spin coating, for example. The thickness of the coating should be
5 at least about 0.3 m, preferably at least about 1- 2 m, but may be much thicker if desired. A one-dip coating using a coating solution comprising about 5 - 8 /a (w/w) of poly(2-phenylethyl acrylate/2-phenylethyl methacrylate) and about 5 % of dibenzoyl peroxiide will give approximately a 0.3 - 0.6 m coating.
Once the coating solution has been contacted with the IOL material to be coated, the coating is allowed to air dry and is then secured to the IOL
material by activating the second stage cross-linking agent. Activation of the second stage cross-linking agent "secuires" the coating to the IOL material by covalently bonding the coating material to the IOL material. Additionally, activation of the 25 second stage cross-linking agent results in cross-linking of the coating material itself. The second stage cross-linking agent can be activated by heating or, particularly for thin (e.g., 0.5 p.m or less) coatings, exposure to electron beam radiation. For example, if the second stage cross-linking agent is dibenzoyl peroxide, the second stage cross-linking agent can be activated by heating at 30 - 100 C for approximately four hours in either a vacuum oven (< 5 mm Hg) or in an inert (e.g., Argon) atmosphere at atmospheric conditions. The temperature and length of exposure to heat are determined by the identity and amount of the second stage cross-linking agent and the desired degree of cross-linking to be SUBSTITUTE SHEET (RULE 26) achieved. In general, however, the temperature will be about 90 C or more where the second stage cross-linking agent is a dibenzoyl peroxide or a substituted dibenzoyl peroxide. In the case where the second stage cross-linking agent is dicumyl peroxide, the activation temperature will be about 125 C or greater. The duration of heating to achieve the second-stage cross-linking is preferably about four times the half-life of the second stage cross-linking agent at the chosen activation temperature. In the case of dicumyl peroxide and an activation temperature of approximately 135 C, the duration of heating is approximately 4 hours. Electron beam sources are commercially available, and include the Min-EB product available from American Intemational Technologies, Inc.
The invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in ,5 other specific forms or variations thereof without departing from its spirit or essential characteristics. The embodiments described above are therefore considered to be illustrative iri all respects and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description.
SUBSTITUTE SHEET (RULE 26)
Once the coating solution has been contacted with the IOL material to be coated, the coating is allowed to air dry and is then secured to the IOL
material by activating the second stage cross-linking agent. Activation of the second stage cross-linking agent "secuires" the coating to the IOL material by covalently bonding the coating material to the IOL material. Additionally, activation of the 25 second stage cross-linking agent results in cross-linking of the coating material itself. The second stage cross-linking agent can be activated by heating or, particularly for thin (e.g., 0.5 p.m or less) coatings, exposure to electron beam radiation. For example, if the second stage cross-linking agent is dibenzoyl peroxide, the second stage cross-linking agent can be activated by heating at 30 - 100 C for approximately four hours in either a vacuum oven (< 5 mm Hg) or in an inert (e.g., Argon) atmosphere at atmospheric conditions. The temperature and length of exposure to heat are determined by the identity and amount of the second stage cross-linking agent and the desired degree of cross-linking to be SUBSTITUTE SHEET (RULE 26) achieved. In general, however, the temperature will be about 90 C or more where the second stage cross-linking agent is a dibenzoyl peroxide or a substituted dibenzoyl peroxide. In the case where the second stage cross-linking agent is dicumyl peroxide, the activation temperature will be about 125 C or greater. The duration of heating to achieve the second-stage cross-linking is preferably about four times the half-life of the second stage cross-linking agent at the chosen activation temperature. In the case of dicumyl peroxide and an activation temperature of approximately 135 C, the duration of heating is approximately 4 hours. Electron beam sources are commercially available, and include the Min-EB product available from American Intemational Technologies, Inc.
The invention has been described by reference to certain preferred embodiments; however, it should be understood that it may be embodied in ,5 other specific forms or variations thereof without departing from its spirit or essential characteristics. The embodiments described above are therefore considered to be illustrative iri all respects and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description.
SUBSTITUTE SHEET (RULE 26)
Claims (39)
1. A coated intraocular lens comprising a substrate material and a coating material for making the intraocular lens more biocompatible and reducing the risk of posterior capsule opacification, wherein the coating material is different than the substrate material and the coating material consists substantially of at least two aryl acrylic hydrophobic monomers of the formula wherein: X is H or CH3;
m is 0-10;
Y is a single bond, 0, S, or NR wherein R is H, CH3, C n H2n+1r wherein n=1-10, iso-OC3H7, C6H5, or CH2C6H5, provided that when m=0, Y is a single bond;
Ar is any aromatic ring which can be unsubstituted or substituted with CH3, C2H5, n-C3H7, iso-C3H7, OCH3, C6H11, Cl, Br, C6H5, or CH2C6H5.
m is 0-10;
Y is a single bond, 0, S, or NR wherein R is H, CH3, C n H2n+1r wherein n=1-10, iso-OC3H7, C6H5, or CH2C6H5, provided that when m=0, Y is a single bond;
Ar is any aromatic ring which can be unsubstituted or substituted with CH3, C2H5, n-C3H7, iso-C3H7, OCH3, C6H11, Cl, Br, C6H5, or CH2C6H5.
2. The coated intraocular lens of claim 1, wherein the aryl acrylic hydrophobic monomers of formula I are chosen from the group consisting of 2-phenoxyethyl acrylate;
2-phenylethylthio acrylate; 2-phenylethylamino acrylate;
phenyl acrylate; benzyl acrylate; 2-phenylethyl acrylate;
3-phenylpropyl acrylate; 3-phenoxypropyl acrylate;
4-phenylbutyl acrylate; 4-phenoxybutyl acrylate;
4-methylphenyl acrylate; 4-methylbenzyl acrylate;
2,2-methylphenylethyl acrylate; 2,3-methylphenylethyl acrylate; 2,4-methylphenylethyl acrylate; and their corresponding methacrylate compounds.
2-phenylethylthio acrylate; 2-phenylethylamino acrylate;
phenyl acrylate; benzyl acrylate; 2-phenylethyl acrylate;
3-phenylpropyl acrylate; 3-phenoxypropyl acrylate;
4-phenylbutyl acrylate; 4-phenoxybutyl acrylate;
4-methylphenyl acrylate; 4-methylbenzyl acrylate;
2,2-methylphenylethyl acrylate; 2,3-methylphenylethyl acrylate; 2,4-methylphenylethyl acrylate; and their corresponding methacrylate compounds.
3. The coated intraocular lens of claim 1, wherein the aryl acrylic hydrophobic monomers of formula I are chosen from the group consisting of 2-phenylethyl acrylate;
2-phenoxyethyl acrylate; 3-phenylpropyl acrylate;
3-phenoxypropyl acrylate; 4-phenylbutyl acrylate;
4-phenoxybutyl acrylate; and their corresponding methacrylate compounds.
2-phenoxyethyl acrylate; 3-phenylpropyl acrylate;
3-phenoxypropyl acrylate; 4-phenylbutyl acrylate;
4-phenoxybutyl acrylate; and their corresponding methacrylate compounds.
4. The coated intraocular lens of claim 1, wherein the aryl acrylic hydrophobic monomers of formula I consist substantially of at least one monomer wherein X = H and at least one monomer wherein X = CH3.
5. The coated intraocular lens of claim 4, wherein the aryl acrylic hydrophobic monomers of formula I are 2-phenylethyl acrylate and 2-phenylethyl methacrylate.
6. The coated intraocular lens of any one of claims 1 to 5, wherein the substrate material is selected from the group consisting of silicone materials, hydrogel materials, and hydrophobic acrylic materials.
7. A method of applying a coating material to an intraocular lens substrate material, wherein the coating material and the substrate material are different and the substrate material comprises an anterior surface and a posterior surface, comprising the steps of a) polymerizing a coating composition consisting substantially of at least two aryl acrylic hydrophobic monomers of the formula wherein: X is H or CH3;
m is 0-10;
Y is a single bond, 0, S, or NR wherein R is H, CH3, C n H2n+1r wherein n=1-10, iso-OC3H7, C6H5, or CH2C6H5, provided that when m=0, Y is a single bond;
Ar is any aromatic ring which can be unsubstituted or substituted with CH3r C2H5, n-C3H7, iso-C3H7, OCH3, C6H11, Cl, Br, C6H5, or CH2C6H5;
and a first stage polymerization initiator selected from the group consisting of thermal initiators and photoinitiators, to form an uncross-linked polymer;
b) dissolving the uncross-linked polymer formed in step (a) in a solvent to form a coating solution;
c) applying the coating solution formed in step (b) to the substrate material; and d) securing the coating solution to the substrate material by activating a second-stage cross-linking agent, provided that at least one of the coating composition of step (a) and the coating solution of step (b) contains the second-stage cross-linking agent, wherein the second-stage cross-linking agent is selected from the group consisting of dibenzoyl peroxide; substituted dibenzoyl peroxide compounds; and dicumyl peroxide.
m is 0-10;
Y is a single bond, 0, S, or NR wherein R is H, CH3, C n H2n+1r wherein n=1-10, iso-OC3H7, C6H5, or CH2C6H5, provided that when m=0, Y is a single bond;
Ar is any aromatic ring which can be unsubstituted or substituted with CH3r C2H5, n-C3H7, iso-C3H7, OCH3, C6H11, Cl, Br, C6H5, or CH2C6H5;
and a first stage polymerization initiator selected from the group consisting of thermal initiators and photoinitiators, to form an uncross-linked polymer;
b) dissolving the uncross-linked polymer formed in step (a) in a solvent to form a coating solution;
c) applying the coating solution formed in step (b) to the substrate material; and d) securing the coating solution to the substrate material by activating a second-stage cross-linking agent, provided that at least one of the coating composition of step (a) and the coating solution of step (b) contains the second-stage cross-linking agent, wherein the second-stage cross-linking agent is selected from the group consisting of dibenzoyl peroxide; substituted dibenzoyl peroxide compounds; and dicumyl peroxide.
8. The method of claim 7, wherein the first stage polymerization initiator is selected from the group consisting of thermal initiators; UV-initiators and blue-light initiators.
9. The method of claim 7 or 8, wherein the solvent in step (b) is 2-pentanone.
10. The method of any one of claims 7 to 9, wherein the coating solution of step (b) is applied to the entire posterior surface of the substrate material.
11. The method of any one of claims 7 to 9, wherein the coating solution of step (b) is applied to only a peripheral band of the posterior surface of the substrate material.
12. The method of any one of claims 7 to 9, wherein the coating solution of step (b) is applied to a peripheral band of the posterior surface of the substrate material and to a peripheral band of the anterior surface of the substrate material.
13. The method of claim 10, wherein the coating solution of step (b) is also applied to a peripheral band of the anterior surface of the substrate material.
14. The method of any one of claims 7 to 13, wherein the second-stage cross-linking agent is selected from the group consisting of dibenzoyl peroxide; dichlorodibenzoyl peroxide; and dicumyl peroxide.
15. The method of any one of claims 7 to 14, wherein the substrate material is exposed to a reactive gas plasma prior to step (c).
16. The method of claim 15, wherein the reactive plasma gas is an oxidizing gas.
17. The method of any one of claims 7 to 16, wherein the coating solution is applied in step (c) by means of dip coating or spin coating.
18. The method of any one of claims 7 to 17, wherein the coating solution applied in step (c) is allowed to air dry prior to activating the second-stage cross-linking agent in step (d).
19. The method of any one of claims 7 to 18, wherein the second-stage cross-linking agent is activated by exposure to heat or electron beam radiation.
20. A coated intraocular lens comprising a substrate material and a coating material for making the intraocular lens more biocompatible and reducing the risk of posterior capsule opacification, wherein the coating material is different than the substrate material and the coating material consists substantially of at least two aryl acrylic hydrophobic monomers of the formula wherein: X is H or CH3;
m is 0-10;
Y is a single bond, O, S, or NR wherein R is H, CH3, C n H2n+1r wherein n=1-10, iso-OC3H7, C6H5, or CH2C6H5, provided that when m=0, Y is a single bond;
Ar is any aromatic ring which can be unsubstituted or substituted with CH3, C2H5, n-C3H7, iso-C3H7, OCH3, C6H11, Cl, Br, C6H5, or CH2C6H5; and one or more ingredients selected from the group consisting of UV absorbing compounds and blue-light absorbing compounds.
m is 0-10;
Y is a single bond, O, S, or NR wherein R is H, CH3, C n H2n+1r wherein n=1-10, iso-OC3H7, C6H5, or CH2C6H5, provided that when m=0, Y is a single bond;
Ar is any aromatic ring which can be unsubstituted or substituted with CH3, C2H5, n-C3H7, iso-C3H7, OCH3, C6H11, Cl, Br, C6H5, or CH2C6H5; and one or more ingredients selected from the group consisting of UV absorbing compounds and blue-light absorbing compounds.
21. The coated intraocular lens of claim 20, wherein the aryl acrylic hydrophobic monomers of formula I are chosen from the group consisting of 2-phenoxyethyl acrylate;
2-phenylethylthio acrylate; 2-phenylethylamino acrylate;
phenyl acrylate; benzyl acrylate; 2-phenylethyl acrylate;
3-phenylpropyl acrylate; 3-phenoxypropyl acrylate;
4-phenylbutyl acrylate; 4-phenoxybutyl acrylate;
4-methylphenyl acrylate; 4-methylbenzyl acrylate;
2,2-methylphenylethyl acrylate; 2,3-methylphenylethyl acrylate; 2,4-methylphenylethyl acrylate; and their corresponding methacrylate compounds.
2-phenylethylthio acrylate; 2-phenylethylamino acrylate;
phenyl acrylate; benzyl acrylate; 2-phenylethyl acrylate;
3-phenylpropyl acrylate; 3-phenoxypropyl acrylate;
4-phenylbutyl acrylate; 4-phenoxybutyl acrylate;
4-methylphenyl acrylate; 4-methylbenzyl acrylate;
2,2-methylphenylethyl acrylate; 2,3-methylphenylethyl acrylate; 2,4-methylphenylethyl acrylate; and their corresponding methacrylate compounds.
22. The coated intraocular lens of claim 20, wherein the aryl acrylic hydrophobic monomers of formula I are chosen from the group consisting of 2-phenylethyl acrylate;
2-phenoxyethyl acrylate; 3-phenylpropyl acrylate;
3-phenoxypropyl acrylate; 4-phenylbutyl acrylate;
4-phenoxybutyl acrylate; and their corresponding methacrylate compounds.
2-phenoxyethyl acrylate; 3-phenylpropyl acrylate;
3-phenoxypropyl acrylate; 4-phenylbutyl acrylate;
4-phenoxybutyl acrylate; and their corresponding methacrylate compounds.
23. The coated intraocular lens of claim 20, wherein the aryl acrylic hydrophobic monomers of formula I consist substantially of at least one monomer wherein X = H and at least one monomer wherein X = CH3.
24. The coated intraocular lens of claim 23, wherein the aryl acrylic hydrophobic monomers of formula I are 2-phenylethyl acrylate and 2-phenylethyl methacrylate.
25. The coated intraocular lens of any one of claims 20 to 24, wherein the substrate material is selected from the group consisting of silicone materials, hydrogel materials, and hydrophobic acrylic materials.
26. A method of applying a coating material to an intraocular lens substrate material, wherein the coating material and the substrate material are different and the substrate material comprises an anterior surface and a posterior surface, comprising the steps of a) polymerizing a coating composition consisting substantially of at least two aryl acrylic hydrophobic monomers of the formula wherein: X is H or CH3;
m is 0-10;
Y is a single bond, 0, S, or NR wherein R is H, CH3, C n H2n+1, wherein n=1-10, iso-OC3H7, C6H5, or CH2C6H5, provided that when m=0, Y is a single bond;
Ar is any aromatic ring which can be unsubstituted or substituted with CH3, C2H5, n-C3H7, iso-C3H7, OCH3, C6H11, Cl, Br, C6H5, or CH2C6H5;
one or more ingredients selected from the group consisting of UV absorbing compounds and blue-light absorbing compounds;
and a first stage polymerization initiator selected from the group consisting of thermal initiators and photoinitiators, to form an uncross-linked polymer;
b) dissolving the uncross-linked polymer formed in step (a) in a solvent to form a coating solution;
c) applying the coating solution formed in step (b) to the substrate material; and d) securing the coating solution to the substrate material by activating a second-stage cross-linking agent, provided that at least one of the coating composition of step (a) and the coating solution of step (b) contains the second-stage cross-linking agent, wherein the second-stage cross-linking agent is selected from the group consisting of dibenzoyl peroxide; substituted dibenzoyl peroxide compounds; and dicumyl peroxide.
m is 0-10;
Y is a single bond, 0, S, or NR wherein R is H, CH3, C n H2n+1, wherein n=1-10, iso-OC3H7, C6H5, or CH2C6H5, provided that when m=0, Y is a single bond;
Ar is any aromatic ring which can be unsubstituted or substituted with CH3, C2H5, n-C3H7, iso-C3H7, OCH3, C6H11, Cl, Br, C6H5, or CH2C6H5;
one or more ingredients selected from the group consisting of UV absorbing compounds and blue-light absorbing compounds;
and a first stage polymerization initiator selected from the group consisting of thermal initiators and photoinitiators, to form an uncross-linked polymer;
b) dissolving the uncross-linked polymer formed in step (a) in a solvent to form a coating solution;
c) applying the coating solution formed in step (b) to the substrate material; and d) securing the coating solution to the substrate material by activating a second-stage cross-linking agent, provided that at least one of the coating composition of step (a) and the coating solution of step (b) contains the second-stage cross-linking agent, wherein the second-stage cross-linking agent is selected from the group consisting of dibenzoyl peroxide; substituted dibenzoyl peroxide compounds; and dicumyl peroxide.
27. A method of applying a coating material to an intraocular lens substrate material, wherein the coating material and the substrate material are different and the substrate material comprises an anterior surface and a posterior surface, comprising the steps of a) polymerizing a coating composition consisting substantially of at least two aryl acrylic hydrophobic monomers of the formula wherein: X is H or CH3;
m is 0-10;
Y is a single bond, O, S, or NR wherein R is H, CH3, CnH2n+1, wherein n=1-10, iso-OC3H7, C6H5, or CH2C6H5, provided that when m=0, Y is a single bond;
Ar is any aromatic ring which can be unsubstituted or substituted with CH3, C2H5, n-C3H7, iso-C3H7, OCH3, C6H11, Cl, Br, C6H5, or CH2C6H5;
and a first stage polymerization initiator selected from the group consisting of thermal initiators and photoinitiators, to form an uncross-linked polymer;
b) dissolving the uncross-linked polymer formed in step (a) in a solvent to form a coating solution, wherein the coating solution further comprises one or more ingredients selected from the group consisting of UV absorbing compounds and blue-light absorbing compounds;
c) applying the coating solution formed in step (b) to the substrate material; and d) securing the coating solution to the substrate material by activating a second-stage cross-linking agent, provided that at least one of the coating composition of step (a) and the coating solution of step (b) contains the second-stage cross-linking agent, wherein the second-stage cross-linking agent is selected from the group consisting of dibenzoyl peroxide; substituted dibenzoyl peroxide compounds; and dicumyl peroxide.
m is 0-10;
Y is a single bond, O, S, or NR wherein R is H, CH3, CnH2n+1, wherein n=1-10, iso-OC3H7, C6H5, or CH2C6H5, provided that when m=0, Y is a single bond;
Ar is any aromatic ring which can be unsubstituted or substituted with CH3, C2H5, n-C3H7, iso-C3H7, OCH3, C6H11, Cl, Br, C6H5, or CH2C6H5;
and a first stage polymerization initiator selected from the group consisting of thermal initiators and photoinitiators, to form an uncross-linked polymer;
b) dissolving the uncross-linked polymer formed in step (a) in a solvent to form a coating solution, wherein the coating solution further comprises one or more ingredients selected from the group consisting of UV absorbing compounds and blue-light absorbing compounds;
c) applying the coating solution formed in step (b) to the substrate material; and d) securing the coating solution to the substrate material by activating a second-stage cross-linking agent, provided that at least one of the coating composition of step (a) and the coating solution of step (b) contains the second-stage cross-linking agent, wherein the second-stage cross-linking agent is selected from the group consisting of dibenzoyl peroxide; substituted dibenzoyl peroxide compounds; and dicumyl peroxide.
28. The method of claim 26 or 27, wherein the first stage polymerization initiator is selected from the group consisting of thermal initiators; UV-initiators and blue-light initiators.
29. The method of any one of claims 26 to 28, wherein the solvent in step (b) is 2-pentanone.
30. The method of any one of claims 26 to 29, wherein the coating solution of step (b) is applied to the entire posterior surface of the substrate material.
31. The method of any one of claims 26 to 29, wherein the coating solution of step (b) is applied to only a peripheral band of the posterior surface of the substrate material.
32. The method of any one of claims 26 to 29, wherein the coating solution of step (b) is applied to a peripheral band of the posterior surface of the substrate material and to a peripheral band of the anterior surface of the substrate material.
33. The method of claim 30, wherein the coating solution of step (b) is also applied to a peripheral band of the anterior surface of the substrate material.
34. The method of any one of claims 26 to 33, wherein the second-stage cross-linking agent is selected from the group consisting of dibenzoyl peroxide; dichlorodibenzoyl peroxide; and dicumyl peroxide.
35. The method of any one of claims 26 to 34, wherein the substrate material is exposed to a reactive gas plasma prior to step (c).
36. The method of claim 35, wherein the reactive plasma gas is an oxidizing gas.
37. The method of any one of claims 26 to 36, wherein the coating solution is applied in step (c) by means of dip coating or spin coating.
38. The method of any one of claims 26 to 37, wherein the coating solution applied in step (c) is allowed to air dry prior to activating the second-stage cross-linking agent in step (d).
39. The method of any one of claims 26 to 38, wherein the second-stage cross-linking agent is activated by exposure to heat or electron beam radiation.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8184298P | 1998-04-15 | 1998-04-15 | |
| US60/081,842 | 1998-04-15 | ||
| PCT/US1999/007363 WO1999052570A1 (en) | 1998-04-15 | 1999-04-01 | Intraocular lens coating compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2317441A1 CA2317441A1 (en) | 1999-10-21 |
| CA2317441C true CA2317441C (en) | 2007-12-18 |
Family
ID=22166749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002317441A Expired - Fee Related CA2317441C (en) | 1998-04-15 | 1999-04-01 | Intraocular lens coating compositions |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6187042B1 (en) |
| EP (1) | EP1071482B1 (en) |
| JP (1) | JP2002511315A (en) |
| CN (1) | CN1161158C (en) |
| AR (1) | AR014986A1 (en) |
| AT (1) | ATE206314T1 (en) |
| AU (1) | AU737675B2 (en) |
| BR (1) | BR9908779A (en) |
| CA (1) | CA2317441C (en) |
| DE (1) | DE69900334T2 (en) |
| DK (1) | DK1071482T3 (en) |
| ES (1) | ES2162518T3 (en) |
| GR (1) | GR3036771T3 (en) |
| PT (1) | PT1071482E (en) |
| WO (1) | WO1999052570A1 (en) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6455318B1 (en) * | 1998-04-15 | 2002-09-24 | Alcon Manufacturing, Ltd. | Collagen IV adhesion assay for intraocular lens materials |
| US6723815B2 (en) * | 1999-09-02 | 2004-04-20 | Alcon, Inc. | Covalently-bound, hydrophilic coating compositions for surgical implants |
| PT1666924E (en) * | 1999-09-02 | 2008-12-26 | Alcon Inc | Covalently-bound hydrophilic coating compositions for implants |
| US6632905B2 (en) | 1999-09-02 | 2003-10-14 | Alcon Universal Ltd. | Covalently-bound, hydrophilic coating compositions for surgical implants |
| AU766394B2 (en) | 1999-09-02 | 2003-10-16 | Alcon Inc. | Hydrophobically-bound, hydrophilic coating compositions for surgical implants |
| DE19955836C1 (en) | 1999-11-19 | 2001-05-17 | Norbert Hampp | Ophthalmic implant |
| US6596026B1 (en) * | 2000-11-27 | 2003-07-22 | Visioncare Ophthalmic Technologies, Inc. | Telescopic intraocular lens |
| US6703466B1 (en) * | 2001-06-18 | 2004-03-09 | Alcon, Inc. | Foldable intraocular lens optics having a glassy surface |
| US20040167621A1 (en) * | 2003-02-26 | 2004-08-26 | Peyman Gholam A. | Teledioptic lens system and method for using the same |
| US7220278B2 (en) * | 2003-02-26 | 2007-05-22 | Minu Telesystems Llc | Teledioptic lens system and method for using the same |
| US20060015180A1 (en) * | 2003-06-06 | 2006-01-19 | Peyman Gholam A | Intraocular telescope |
| US20050288784A1 (en) * | 2004-06-23 | 2005-12-29 | Peyman Gholam A | Bifocal intraocular telescope for low vision correction |
| US20040267359A1 (en) | 2003-06-27 | 2004-12-30 | Harish Makker | IOL insertion apparatus and methods for making and using same |
| US20050055091A1 (en) * | 2003-09-08 | 2005-03-10 | Yu-Chin Lai | Process for making silicone intraocular lens with blue light absorption properties |
| US20050085908A1 (en) * | 2003-10-20 | 2005-04-21 | Chang Yu-An | New ophthalmic lens materials with high refractive index and biocompatible surface |
| EP1689333B1 (en) * | 2003-12-05 | 2014-02-12 | Innfocus, Inc. | Improved glaucoma implant device |
| EP1696831B1 (en) * | 2003-12-05 | 2014-01-15 | Innolene LLC | Method of producing a refractive ocular lens |
| CA2552122A1 (en) * | 2003-12-29 | 2005-07-21 | Advanced Medical Optics, Inc. | Intraocular lenses having a visible light-selective-transmissive-region |
| AU2005242823B2 (en) | 2004-04-30 | 2011-04-14 | Johnson & Johnson Surgical Vision, Inc. | Ophthalmic devices having a highly selective violet light transmissive filter and related methods |
| US7157538B2 (en) | 2004-08-13 | 2007-01-02 | Alcon, Inc. | Covalently-bound, hydrophilic coating compositions for surgical implants |
| JP4906257B2 (en) | 2004-11-10 | 2012-03-28 | Ｈｏｙａ株式会社 | Method for producing surface-treated intraocular lens and intraocular lens for inhibiting secondary cataract |
| BRPI0518030A (en) | 2004-11-22 | 2008-10-28 | Advanced Medical Optics Inc | copolymerizable methane and anthraquinone compounds and articles containing them |
| ATE549649T1 (en) * | 2004-11-22 | 2012-03-15 | Abbott Medical Optics Inc | COPOLYMERIZABLE AZONE COMPOUNDS AND ITEMS CONTAINING THEM |
| JP2006238914A (en) * | 2005-02-28 | 2006-09-14 | Hoya Corp | Intraocular lens and its manufacturing method |
| US7892284B2 (en) | 2005-02-28 | 2011-02-22 | Hoya Corporation | Intraocular lens and process for producing the same |
| WO2006095750A1 (en) * | 2005-03-09 | 2006-09-14 | Hoya Corporation | (meth)acrylate compound, process for production of the compound, (meth)acrylate copolymer, process for production of the copolymer, and soft intraocular lens |
| US7495061B2 (en) * | 2005-05-27 | 2009-02-24 | Bausch + Lomb Incorporated | High refractive-index, hydrophilic monomers and polymers, and ophthalmic devices comprising such polymers |
| CN101321505B (en) * | 2005-09-08 | 2015-12-02 | 卡尔豪恩视觉公司 | There is the novel adjustable optical elements strengthening ultraviolet protection |
| JP2009045329A (en) * | 2007-08-22 | 2009-03-05 | Hoya Corp | Intraocular lens and its manufacturing method |
| WO2009102454A1 (en) * | 2008-02-12 | 2009-08-20 | Aaren Scientific Inc. | Ophthalmic lens having a yellow dye light blocking component |
| US9232993B2 (en) * | 2008-04-04 | 2016-01-12 | Battelle Memorial Institute | Adjustable intraocular lens |
| US10018853B2 (en) | 2008-04-04 | 2018-07-10 | Battelle Memorial Institute | Methods of altering the refractive index of materials |
| US10254562B2 (en) | 2008-04-04 | 2019-04-09 | Battelle Memorial Institute | Methods for tailoring the refractive index of lenses |
| US8222360B2 (en) | 2009-02-13 | 2012-07-17 | Visiogen, Inc. | Copolymers for intraocular lens systems |
| TWI507183B (en) * | 2009-09-04 | 2015-11-11 | Alcon Inc | Intraocular lenses with interlenticular opacification resistance |
| JP2013523273A (en) * | 2010-03-31 | 2013-06-17 | ノバルティス アーゲー | Adjustable intraocular lens system |
| US9827088B2 (en) * | 2013-09-12 | 2017-11-28 | Battelle Memorial Institute | Methods of altering the refractive index of materials |
| WO2015084788A1 (en) | 2013-12-04 | 2015-06-11 | Novartis Ag | Soft acrylic materials with high refractive index and minimized glistening |
| CN103948965B (en) * | 2014-04-30 | 2015-12-09 | 华南理工大学 | A kind of intraocular lens of surface modification and surface modifying method |
| WO2016133656A1 (en) * | 2015-02-16 | 2016-08-25 | Novartis Ag | Wet-pack intraocular lens materials with high refractive index |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4515794A (en) | 1981-10-09 | 1985-05-07 | Baylor College Of Medicine | Mitotic inhibitors preventing posterior lens capsule opacification |
| US4731080A (en) * | 1985-01-18 | 1988-03-15 | Galin Miles A | Coated intraocular lens |
| US4725276A (en) | 1986-09-04 | 1988-02-16 | Precision-Cosmet Co., Inc. | Intraocular lens with continuous posterior ring-like member |
| US5236970A (en) | 1987-02-05 | 1993-08-17 | Allergan, Inc. | Optically clear reinforced silicone elastomers of high optical refractive index and improved mechanical properties for use in intraocular lenses |
| US4918165A (en) | 1987-07-16 | 1990-04-17 | Ophthalmic Research Corporation | Mitotic inhibitor and method for preventing posterior lens capsule opacification after extracapsular extraction |
| US4846833A (en) | 1988-05-25 | 1989-07-11 | Cumming J S | Sealed fresnel intraocular lens |
| US5002571A (en) | 1989-02-06 | 1991-03-26 | Donnell Jr Francis E O | Intraocular lens implant and method of locating and adhering within the posterior chamber |
| US4950290A (en) | 1989-02-09 | 1990-08-21 | William Kamerling | Posterior chamber intraocular lens |
| US5078740A (en) | 1990-04-02 | 1992-01-07 | Walman Gerald B | Intraocular lens |
| US5057578A (en) | 1990-04-10 | 1991-10-15 | E. I. Du Pont De Nemours And Company | Silicone-containing block copolymers and macromonomers |
| US5371147A (en) | 1990-10-11 | 1994-12-06 | Permeable Technologies, Inc. | Silicone-containing acrylic star polymers, block copolymers and macromonomers |
| US5290892A (en) * | 1990-11-07 | 1994-03-01 | Nestle S.A. | Flexible intraocular lenses made from high refractive index polymers |
| JP2724931B2 (en) * | 1990-11-07 | 1998-03-09 | ネッスル エス エー | Copolymer and intraocular lens using the copolymer |
| US5135297A (en) | 1990-11-27 | 1992-08-04 | Bausch & Lomb Incorporated | Surface coating of polymer objects |
| DE69211152T2 (en) | 1991-11-05 | 1997-01-02 | Bausch & Lomb | COMPOSITIONS OF WETABLE SILICONE HYDROGELS AND METHOD FOR THE PRODUCTION THEREOF |
| AU3075792A (en) | 1991-11-14 | 1993-06-15 | Stanley Poler | Secondary eye growth impeding device and method |
| US5405385A (en) | 1992-04-02 | 1995-04-11 | Clemson University | Intraocular lens with integrated means of fixation |
| US5331073A (en) | 1992-11-09 | 1994-07-19 | Allergan, Inc. | Polymeric compositions and intraocular lenses made from same |
| US5336797A (en) | 1992-12-30 | 1994-08-09 | Bausch & Lomb Incorporated | Siloxane macromonomers |
| US5375611A (en) | 1993-01-26 | 1994-12-27 | Pharmacia Ab | Method for preventing secondary cataract |
| SE9301422D0 (en) | 1993-04-28 | 1993-04-28 | Kabi Pharmacia Ab | METHOD AND MEANS FOR INHIBITING POSTERIOR CAPSULE OPACIFICATION |
| US5366501A (en) | 1993-05-12 | 1994-11-22 | Langerman David W | Intraocular lens with dual 360 degree haptics |
| US5876438A (en) | 1993-08-02 | 1999-03-02 | Houston Biotechnology Incorporated | Polymeric device for the delivery of immunotoxins for the prevention of secondary cataract |
| US5470932A (en) * | 1993-10-18 | 1995-11-28 | Alcon Laboratories, Inc. | Polymerizable yellow dyes and their use in opthalmic lenses |
| US5618316A (en) * | 1993-12-14 | 1997-04-08 | Hoffman; Allan S. | Polyethylene oxide coated intraocular lens |
| SE503711C2 (en) * | 1994-12-14 | 1996-08-12 | Medicarb Ab | Multistage procedure for coating an intraocular lens |
| US5593438A (en) | 1995-01-20 | 1997-01-14 | Akhavi; David S. | Intraocular lens with metallic coatings for preventing secondary cataracts |
| JP2967093B2 (en) | 1995-02-23 | 1999-10-25 | ホーヤ株式会社 | Flexible intraocular lens |
| SE9501671D0 (en) | 1995-05-05 | 1995-05-05 | Pharmacia Ab | Method and composition for prevention of posterior capsule opacification |
| US5549670A (en) | 1995-05-09 | 1996-08-27 | Allergan, Inc. | IOL for reducing secondary opacification |
| US5693094A (en) | 1995-05-09 | 1997-12-02 | Allergan | IOL for reducing secondary opacification |
| WO1996040303A1 (en) * | 1995-06-07 | 1996-12-19 | Alcon Laboratories, Inc. | Improved high refractive index ophthalmic lens materials |
| US5714557A (en) | 1995-12-07 | 1998-02-03 | Bausch & Lomb Incorporated | Monomeric units useful for reducing the modulus of low water polymeric silicone compositions |
| EP0781777A1 (en) | 1995-12-28 | 1997-07-02 | Menicon Co., Ltd. | Silicon-containing compound and ocular lens material |
| US5733276A (en) | 1996-08-20 | 1998-03-31 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Method for prophylactic therapy for post-operative posterior capsular opacification |
| FR2754173B1 (en) | 1996-10-07 | 1998-12-24 | Corneal Ind | DEVICE FOR TENSIONING THE CRYSTALLINE CAPSULE, LIKELY TO BE CHARGED WITH AT LEAST ONE ACTIVE PRINCIPLE AND TO RELEASE THE ACTIVE PRINCIPLE, AND ITS PREPARATION |
| US5891931A (en) * | 1997-08-07 | 1999-04-06 | Alcon Laboratories, Inc. | Method of preparing foldable high refractive index acrylic ophthalmic device materials |
| JP3805496B2 (en) | 1997-08-29 | 2006-08-02 | 株式会社ニデック | Intraocular lens |
| US6027531A (en) | 1997-10-14 | 2000-02-22 | Tassignon; Marie-Joseb. R. | Intraocular lens and method for preventing secondary opacification |
| US6162249A (en) | 1998-05-29 | 2000-12-19 | Allergan | IOI for inhibiting cell growth and reducing glare |
-
1999
- 1999-04-01 BR BR9908779-0A patent/BR9908779A/en not_active Application Discontinuation
- 1999-04-01 US US09/283,701 patent/US6187042B1/en not_active Expired - Fee Related
- 1999-04-01 EP EP99915253A patent/EP1071482B1/en not_active Expired - Lifetime
- 1999-04-01 CA CA002317441A patent/CA2317441C/en not_active Expired - Fee Related
- 1999-04-01 AU AU33810/99A patent/AU737675B2/en not_active Ceased
- 1999-04-01 AT AT99915253T patent/ATE206314T1/en active
- 1999-04-01 PT PT82304018T patent/PT1071482E/en unknown
- 1999-04-01 WO PCT/US1999/007363 patent/WO1999052570A1/en active IP Right Grant
- 1999-04-01 JP JP2000543180A patent/JP2002511315A/en active Pending
- 1999-04-01 DE DE69900334T patent/DE69900334T2/en not_active Expired - Lifetime
- 1999-04-01 DK DK99915253T patent/DK1071482T3/en active
- 1999-04-01 CN CNB998032999A patent/CN1161158C/en not_active Expired - Fee Related
- 1999-04-01 ES ES99915253T patent/ES2162518T3/en not_active Expired - Lifetime
- 1999-04-15 AR ARP990101743A patent/AR014986A1/en unknown
-
2001
- 2001-10-01 GR GR20010401631T patent/GR3036771T3/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69900334D1 (en) | 2001-11-08 |
| GR3036771T3 (en) | 2002-01-31 |
| AU3381099A (en) | 1999-11-01 |
| BR9908779A (en) | 2000-12-05 |
| CN1291901A (en) | 2001-04-18 |
| DK1071482T3 (en) | 2001-12-27 |
| CA2317441A1 (en) | 1999-10-21 |
| PT1071482E (en) | 2002-02-28 |
| JP2002511315A (en) | 2002-04-16 |
| AU737675B2 (en) | 2001-08-30 |
| ATE206314T1 (en) | 2001-10-15 |
| AR014986A1 (en) | 2001-04-11 |
| US6187042B1 (en) | 2001-02-13 |
| EP1071482B1 (en) | 2001-10-04 |
| DE69900334T2 (en) | 2002-04-25 |
| EP1071482A1 (en) | 2001-01-31 |
| CN1161158C (en) | 2004-08-11 |
| WO1999052570A1 (en) | 1999-10-21 |
| ES2162518T3 (en) | 2001-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2317441C (en) | Intraocular lens coating compositions | |
| US6632887B2 (en) | Coating compositions and methods for reducing edge glare in implantable ophthalmic lenses | |
| CA2317757C (en) | Bicomposite intraocular lens and method for its preparation | |
| AU2001288418B2 (en) | Switchable tackiness coating compositions for ophthalmic implants | |
| US6703466B1 (en) | Foldable intraocular lens optics having a glassy surface | |
| US20010014824A1 (en) | Toric intraocular lens material | |
| AU2001288418A1 (en) | Switchable tackiness coating compositions for ophthalmic implants | |
| JP2011229981A (en) | Covalently-bound, hydrophilic coating composition for surgical implant | |
| US6632905B2 (en) | Covalently-bound, hydrophilic coating compositions for surgical implants | |
| CA2381270C (en) | Hydrophobically-bound, hydrophilic coating compositions for surgical implants | |
| AU768090B2 (en) | Coating of implantable ophthalmic lenses to reduce edge glare |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20130402 |